KKR is all set to acquire Healthium Medtech ( formerly Sutures India) from its current PE owners Apax Partners for Rs 7000 crore ($840 mn) enterprise value after a hotly contested three way race that also included a consortium of Mankind Pharma - ChrysCapital and Novo Holdings, the controlling shareholders of Danish drug major Novo Nordisk, said people aware.

知情人士称，经过一场激烈竞争的三方竞争，KKR已准备好以7亿卢比（8.4亿美元）的企业价值从其目前的PE所有者Apax Partners手中收购Healthium Medtech（前身为Suthures India），这场竞争还包括一个由人类制药公司（Humand Pharma）组成的财团-ChrysCapital和丹麦制药巨头诺和诺德（Novo Nordisk）的控股股东诺和诺德（Novo Holdings）。

KKR and Apax have signed the binding agreement for the acquisition of Bengaluru based Healthium Medtech and likely to make a formal announcement as early as Monday, the people mentioned above added. Healthium is the largest manufacturer of surgical needles globally by volume. Moneycontrol was the first to report on Saturday that KKR was the highest bidder for Healthium.Another contender Mankind-ChrysCapital has offered a price of Rs6500 crore ($780 mn), said sources.Apax owns 99.8% of the company with the rest 0.2% owned by Anish Bafna, the CEO & MD of Healthium Medtech.

上述人士补充称，KKR和Apax已经签署了收购总部位于班加罗尔的Healthium Medtech的具有约束力的协议，并可能最早于周一正式宣布。Healthium是全球最大的手术针生产商。Moneycontrol是周六第一个报告称KKR是Healthium的最高出价者。消息人士称，另一竞争对手HumanChryscapital出价65亿卢比（7.8亿美元）。Apax拥有该公司99.8%的股份，其余0.2%的股份由Healthium Medtech的首席执行官兼医学博士AnishBafna拥有。

Healthium is the fourth largest surgical suture manufacturer in the world with a market share of about 18% in India. Bafna will continue to run the company under KKR. When contacted, Apax Partners, KKR spokespersons declined to comment.Earlier in 2022, Healthium Medtech had sold its UK-based subsidiary to KKR for an undisclosed amount.

Healthium是世界第四大外科缝线制造商，在印度的市场份额约为18%。Bafna将继续在KKR管理下运营公司。与Apax Partners、KKR发言人联系时，拒绝置评。2022年早些时候，Healthium Medtech将其英国子公司出售给KKR，金额未披露。

It had sold Watford-based Clinisupplies to KKR Health Care Strategic Growth Fund II.Sutures India was originally set up in 1992 in Bengaluru by LG Chandrasekhar and S Subramanium, former executives with Smith & Nephew, and Johnson & Johnson.In FY24, the company posted Rs 820 crore in revenue and Rs 256 crore ebitda.

它已将总部位于沃特福德的Clinisupplies出售给KKR医疗保健战略增长基金II。Suthures India最初由LG Chandrasekhar和S Subramanium于1992年在班加罗尔成立，他们是Smith＆Nephew和Johnson＆Johnson的前高管。2014财年，该公司收入为82亿卢比，息税折旧摊销前利润为2.56亿卢比。

This financial year, revenue is expected to reach Rs 1,020 crore with ebitda at around Rs 350 crore. The transaction then is being done at 20X the current EBITDA multiple of the current fiscal FY25.Ethic.

本财年，预计收入将达到10.2亿卢比，息税折旧摊销前利润约为3.5亿卢比。然后，该交易以当前25财年息税折旧摊销前利润倍数的20倍完成。